(Q39588867)

13 September 2017

Inhibition of human gamma delta [corrected] T-cell antitumoral activity through HLA-G: implications for immunotherapy of cancer (English)

1 reference

13 September 2017

1 reference

Emilie Lesport

1

0 references

Alessia Zamborlini

Alessia Zamborlini

5

0 references

Joel LeMaoult

Joel LeMaoult

4

0 references

Edgardo D. Carosella

7

Edgardo D Carosella

1 reference

13 September 2017

Nathalie Rouas-Freiss

6

Nathalie Rouas-Freiss

1 reference

13 September 2017

Jeremy Baudhuin

2

1 reference

13 September 2017

Sylvie Sousa

3

1 reference

13 September 2017

Benoit Favier

8

1 reference

13 September 2017

20 February 2011

1 reference

Cellular and Molecular Life Sciences

13 September 2017

1 reference

13 September 2017

68

1 reference

13 September 2017

20

1 reference

13 September 2017

3385-3399

1 reference

https://scigraph.springernature.com/pub.10.1007/s00018-011-0632-7

13 September 2017

0 references

cites work

[gamma][delta] cells: a right time and a right place for a conserved third way of protection

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0632-7

Gammadelta T cells and the lymphoid stress-surveillance response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0632-7

Self/non-self discrimination by human gammadelta T cells: simple solutions for a complex issue?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0632-7

Human Vgamma9Vdelta2 T cells: from signals to functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0632-7

MICA expressed by multiple myeloma and monoclonal gammopathy of undetermined significance plasma cells Costimulates pamidronate-activated gammadelta lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0632-7

Activation of V gamma 9V delta 2 T cells by NKG2D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0632-7

Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0632-7

Gammadelta T cells for immune therapy of patients with lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0632-7

Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0632-7

Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0632-7

Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0632-7

Pitfalls on the roadmap to gammadelta T cell-based cancer immunotherapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0632-7

Expression of tolerogenic HLA-G molecules in cancer prevents antitumor responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0632-7

Biology of HLA-G in cancer: a candidate molecule for therapeutic intervention?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0632-7

The role of HLA-G in immunity and hematopoiesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0632-7

Research on HLA-G: an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0632-7

Beyond the increasing complexity of the immunomodulatory HLA-G molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0632-7

HLA-G: from biology to clinical benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0632-7

The alpha1 domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural killer cells: is HLA-G the public ligand for natural killer cell inhibitory receptors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0632-7

HLA-G-mediated inhibition of antigen-specific cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0632-7

HLA-G2, -G3, and -G4 isoforms expressed as nonmature cell surface glycoproteins inhibit NK and antigen-specific CTL cytolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0632-7

In vivo immunomanipulation of V gamma 9V delta 2 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0632-7

Switch of HLA-G alternative splicing in a melanoma cell line causes loss of HLA-G1 expression and sensitivity to NK lysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0632-7

Evidence to support the role of HLA-G5 in allograft acceptance through induction of immunosuppressive/ regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0632-7

Complex interplay of activating and inhibitory signals received by Vgamma9Vdelta2 T cells revealed by target cell beta2-microglobulin knockdown

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0632-7

IL-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human V gamma 9V delta 2 T cells for adoptive immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0632-7

Soluble HLA-G protein secreted by allo-specific CD4+ T cells suppresses the allo-proliferative response: a CD4+ T cell regulatory mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0632-7

Soluble HLA-G inhibits cell cycle progression in human alloreactive T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0632-7

Complexes of HLA-G protein on the cell surface are important for leukocyte Ig-like receptor-1 function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0632-7

Tolerization of dendritic cells by HLA-G.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0632-7

A homodimeric complex of HLA-G on normal trophoblast cells modulates antigen-presenting cells via LILRB1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0632-7

Secretion of pro-apoptotic intron 4-retaining soluble HLA-G1 by human villous trophoblast.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0632-7

The Ki-67 protein: from the known and the unknown

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0632-7

Gammadelta T cells: functional plasticity and heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0632-7

A gamma delta T cell specific surface receptor (WC1) signaling G0/G1 cell cycle arrest

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0632-7

Bridging innate and adaptive immunity through gammadelta T-dendritic cell crosstalk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0632-7

HLA class I molecules regulate IFN-gamma production induced in NK cells by target cells, viral products, or immature dendritic cells through the inhibitory receptor ILT2/CD85j

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0632-7

ILT2/HLA-G interaction impairs NK-cell functions through the inhibition of the late but not the early events of the NK-cell activating synapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0632-7

Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0632-7

Control of self-reactive cytotoxic T lymphocytes expressing gamma delta T cell receptors by natural killer inhibitory receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0632-7

Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0632-7

Coordinated expression of Ig-like inhibitory MHC class I receptors and acquisition of cytotoxic function in human CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0632-7

Inhibition of the activating signals in NK92 cells by recombinant GST-sHLA-G1a chain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0632-7

Human melanoma cell secreting human leukocyte antigen-G5 inhibit natural killer cell cytotoxicity by impairing lytic granules polarization toward target cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0632-7

MICA triggering signal for NK cell tumor lysis is counteracted by HLA-G1-mediated inhibitory signal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0632-7

Uncoupling between Immunological Synapse Formation and Functional Outcome in Human γδ T Lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0632-7

Perspectives of gammadelta T cells in tumor immunology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0632-7

Human Vgamma9Vdelta2 T cells: promising new leads for immunotherapy of infections and tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0632-7

HLA-G in B-chronic lymphocytic leukaemia: clinical relevance and functional implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0632-7

Expression and regulation of non-classical HLA-G in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0632-7

Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0632-7

Increased expression of the natural killer cell inhibitory receptor CD85j/ILT2 on antigen-specific effector CD8 T cells and its impact on CD8 T-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-011-0632-7

Characterization of HLA-G expression in renal cell carcinoma

21 January 2018

1 reference

12 December 2020

Mechanisms of prolongation of allograft survival by HLA-G/ILT4-modified dendritic cells

1 reference

12 December 2020

HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas

1 reference

12 December 2020

Natural killer cell functional activity suppression by intravenous immunoglobulin, intralipid and soluble human leukocyte antigen-G

1 reference

12 December 2020

Transcription factor E2F controls the reversible gamma delta T cell growth arrest mediated through WC1

1 reference

12 December 2020

Soluble HLA-G generated by proteolytic shedding inhibits NK-mediated cell lysis

1 reference

12 December 2020

CD94/NKG2 inhibitory receptor complex modulates both anti-viral and anti-tumoral responses of polyclonal phosphoantigen-reactive V gamma 9V delta 2 T lymphocytes

1 reference

12 December 2020

Control of B cell lymphoma recognition via natural killer inhibitory receptors implies a role for human Vgamma9/Vdelta2 T cells in tumor immunity

1 reference

12 December 2020

HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients

1 reference

12 December 2020

HLA-G is a potential tumor marker in malignant ascites

1 reference

12 December 2020

Soluble HLA-G molecules are increased in lymphoproliferative disorders

1 reference

12 December 2020

Soluble HLA-A,-B,-C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation

1 reference

12 December 2020

Growth arrest of gammadelta T cells induced by monoclonal antibody against WC1 correlates with activation of multiple tyrosine phosphatases and dephosphorylation of MAP kinase erk2

1 reference

12 December 2020

10.1007/S00018-011-0632-7

Identifiers

DOI

1 reference

13 September 2017

1 reference